The World Health Organization has declared the Ebola outbreak caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda a Public Health Emergency of International Concern, citing cross-border spread, rising suspected cases, and the absence of approved vaccines or treatments.
Preclinical in vitro and animal models remain essential for establishing antibiotic pharmacokinetic and pharmacodynamic targets, but experts say translating those findings into real-world patient care requires careful consideration of host factors, tissue penetration and clinical context.
New phase 3 data from the SCORPIO-PEP study showed that a 5-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 after household exposure, highlighting its potential to transform prevention strategies for high-risk populations and future variant-driven surges.
Leaders from SIDP and MAD-ID highlighted their new partnership and announced the launch of the “Antimicrobials” meeting in 2027, focused on combining cutting-edge science with clinical antimicrobial practice.
Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations.
SIDP President Erin McCreary, PharmD, BCIDP, FIDSA, explains how the new partnership between SIDP and MAD-ID brings together organizations with shared leadership and values to create a more accessible, collaborative meeting space for infectious diseases pharmacists and related specialties.
David Ha, PharmD, offers insights on how to build out a successful practice-based research project, including developing a strong research question, understanding IRB requirements early, and leveraging reliable institutional data sources and collaborations.
In the second installment of our interview with Andrew Handel, MD, he provides insights on Lyme Disease treatment in the pediatric population.
Stephanie Spivack, MD, discusses an upcoming healthcare provider symposium that will provide education around treating novel infections for patients with substance use disorder (SUD).
The University of Nebraska's Mark Rupp, MD, weighs in on his institution's facilities where passengers are being housed during the quarantine protocol, insights on how they are monitored, and their current medical conditions.
With spring here and tick bites on the rise, Andrew Handel, MD, provides tips on prevention as well as when to consider medical care for a bite.
Federal agencies have airlifted 17 American citizens from the MV Hondius to Nebraska for evaluation and care following exposure to the Andes variant of hantavirus. One passenger currently has mild symptoms and another passenger tested mildly PCR positive for the Andes virus.
Universal childhood immunizations should continue to include hepatitis A to avoid reversing 3 decades of progress toward eliminating the infection, say contributors to the previous, long-standing CDC guidance.
This week, listen to a clinician who has treated hantavirus, SIDP's latest column on the effects of antimicrobials on the microbiome, our podcast looking at how AI can help with stewardship, and more.
Luis A. Marcos, MD, who has treated a patient with hantavirus, provides insights around the Andes virus, which is the species involved in the ongoing outbreak cluster on the cruise ship, as well as its transmissibility and treatment.
Systemic antibiotic therapy often leads to significant long-term disruptions to the gut microbiome. In addition to antibiotic stewardship, use of prebiotic fiber, fermented foods, and probiotics is a recommended strategy to minimize microbiome disruption and reestablish a healthy, diverse gut microbial population.
The growing incidence of resistant Gram-negative infections in hospitals is being fueled by evolving resistance mechanisms, antibiotic overuse, and the rapid global spread of mobile genetic elements. Mariana Castanheira, PhD, FIDSA, FAAM, chief scientific officer at JMI Laboratories, discusses this topic and an agent with utility against pathogens carrying Metallo-beta-lactamases (MBLs).
Eolas Medical has an AI-powered clinical platform looking to aid health care professionals in accessing localized antimicrobial guidelines instantly, improving prescribing accuracy, reducing errors, and strengthening patient safety. CEO Declan Kelly, MBBS, provides insights on the platform and how his company is trying to address gaps in antimicrobial stewardship.
In this month's column, we talk to leaders from professional medical organizations about the revised Advisory Committee on Immunization Practices charter as well as commentary about the Centers for Disease Control and Prevention’s suppression of COVID-19 vaccine data.
Mortality rates from treatment-resistant gram-negative infections remain high despite increased use of newer antibiotics and corresponding susceptibility testing.
This week, read about shorter treatment duration for community-acquired pneumonia, how integrating hepatitis C EMR prompts and innovative community outreach are increasing patients getting tested and treated, and how professional medical organizations are leading the fight for vaccines.
Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses the need to be transparent and publish the latest vaccine data, and offers clinical insights around their safety and efficacy.
Pruthvi Patel, MD, MPH, discusses how she is integrating hepatitis C EMR prompts at her institution as well as their innovative community outreach with educators to get more people into the care continuum.
New real-world data from the CIRCE study underscore cefiderocol’s potential in treating metallo-beta-lactamase–producing Enterobacterales infections, particularly among critically ill and immunocompromised patients with limited therapeutic options. Christine Slover, PharmD, offers some insights around the study and these infections.
In the second episode with Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, he discusses the federal government's attempts to suppress studies on vaccine data and how it continues the ongoing antivaccine ideology with further mis- and disinformation.
Gilead Sciences will receive FDA review for its investigational bictegravir/lenacapavir (BIC/LEN) single-tablet HIV regimen, with a decision expected by late summer.
Robert H. Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, offers commentary about what changing the vaccine committee’s charter means from a functional standpoint and how it affects public health by moving away from vaccines as a prevention strategy.
Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, offers insights on what the changing Advisory Committee on Immunization Practices charter means and legal steps the college is taking to prevent the federal government’s attempt to reshape the group and vaccine policy in the US.
Real-world data suggest that 3 to 4 days of antibiotics can be as effective as 5 or more days in treating community-acquired pneumonia in hospitalized patients.
A study assessing the local transmission found it caused 14 confirmed cases in 2024 and exposed diagnostic delays in patients without travel history.
